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The treatment of chronic hepatitis C (CHC) with peginterferon alpha-2b/ribavirin (PegIFN + Rib) produced larger
sustained viral response (SVR) compared to the conventional (non-pegylated) interferon/ribavirin (IFN + Rib), but
its cost-effectiveness was not assessed in Brazil. We developed a Markov model to mirror the natural disease history
and cohorts of patients with hepatitis C virus (HCV), that received PegIFN + Rib or IFN + Rib treatment for 48 or 24
weeks, according to viral genotype and liver histology. The SVRs for the treatments PegIFN + Rib and IFN + Rib
were respectively 48% and 34% (genotype 1), and 88% and 80% (genotype non-1). Three Delphi panels were
conducted with hepatologists and intensivists, and another one with oncologists. The costs are expressed in 2006
Brazilian Reais (R$) and the benefits were discounted at 3%. In genotype 1 HCV patients, PegIFN + Rib increases
the life expectancy (LE) in 0.51 year, and the quality-adjusted life years (QALY) in 0.78, as compared to IFN + Rib.
In genotype non-1 HCV patients, PegIFN + Rib increases the LE in 0.29 years and the QALY in 0.44 years, as
compared to IFN + Rib. The incremental cost-effectiveness rate, considering all the genotypes, was of R$19,848.34
per QALY. Peginterferon alpha-2b with ribavirin is a cost-effective therapy for the treatment of naïve CHC adult
patients compared to the interferon alpha-2b and ribavirin regime, irrespective of the viral genotype.
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Hepatitis C is an infection generally presenting a slow
progression [1], and its occurrence and prevalence within the
population was not yet completely elucidated [2].
In a study developed in the city of São Paulo, an estimate
prevalence of 1.42% (CI 0.70% - 2.42%) for hepatitis C was
found, which, when projected to the entire Brazilian territory,
results in a figure between 1.1 and 3.4 million of HCV infected
people [2].
Hepatitis C virus (HCV) genotyping is important to define
the treatment time: 48 weeks for genotype 1 and 24 weeks for
other genotypes. The treatment aim is to achieve a sustained
viral response (SVR), which is defined as the absence of
detection of serum HCV RNA at the treatment final, and six
months later as well; to confirm this condition, an essay with
sensitivity of, at least, 100 copies (50 IU) per milliliter was
used.
Interferon alpha/ribavirin (IFN + Rib) association has
become the treatment gold-standard for C hepatitis from 1998
on [3].
In order to improve the efficacy, side effects profile and
the therapeutic scheme itself, pegylated-interferons alpha
(PegIFN) have been developed, and are currently considered
as the treatment gold-standard for hepatitis C [4].
There are two different products available in the Brazilian
market, the peginterferon alpha 2b weighing 12 kD, and the
peginterferon alpha 2a weighing 40 KD.
In two multicentric, double-blind, randomized clinical trials
using ribavirin in both treatment arms (“IFN” arm and
“PegIFN” arm), the global SVR rate achieved by peginterferon
alpha 2a was 56% [5], and by peginterferon alpha 2b 54% [6].
The health system is concerned about hepatitis C, because
the great period of infection for this disease occurred in the
80’s [7], and, taking in account the disease progression [6]
and that the therapeutic results are not yet satisfactory, it is
expected that the great impact, in terms of number of people
carrying the disease as well as the costs involved, will occur
in the first two decades of this third millennium.
Due to the clinical course of the infection, it is improper or
even feasible to conduct controlled and randomized clinical
trials, to investigate the medical-economic impact that better
SVR rates could represent [8].
It is unknown whether the short-term costs will be
compensated by the possible savings (lesser complications
and transplantations) or, even, the extension in which better
response rates from pegylated interferons will represent, in
terms of life years or quality of life.
As treatment decisions have to be taken right now, we
built an analytic decision model to assess both the long-term
‘clinical’ and ‘cost-effectiveness’ results that are currently
obtained from the treatment of chronic hepatitis C in Brazil,
using for this purpose the best available information, although
still imperfect [8].
Material and Methods
We built the model using decision analysis techniques
[9]. The analysis was developed in a hypothetical cohort of
30 year-old men and women with chronic hepatitis C, settled
in the 2006 Brazilian health system. The primary study
perspective is that of private medicine (insurances, HMOs,
cooperatives, self-managements).
The adopted data sources were the medical literature [6];
published official prices for medications, procedures, and
hospital supplies; and Brazilian population statistics.
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The determination of actual costs of hepatitis C treatment
was performed through a microcosting process based on
modified Delphi panels [10].
Values should be divided by 2.18 to convert the economic
result to 2006 US dollars.
Markov Model for Chronic Hepatitis C
A Markov model has been developed for the natural
history of chronic hepatitis C.
The health status were based on histology, presence or
absence of viremia; presence of uncompensated hepatic
disease; hepatocellular carcinoma or hepatic
transplantation; describing the following conditions:
remission, mild hepatitis C, moderate hepatitis C,
hepatocarcinoma, cirrhosis or uncompensated cirrhosis, to
be submitted to hepatic transplantation, to be transplanted,
and death. Due to the large variability in treatment and
costs, uncompensated cirrhosis health status, was further
split in ascytis, refractory ascytis, hemorrhagic varices and
hepatic encephalopathy. The prevalence of genotype 1 in
Brazil is 74% [2].
The simulation starts after the diagnose of chronic
hepatitis C, and assumes three groups of patients: one treated
with conventional IFN, another with PegIFN alpha 2b of 12
kD, and a non-treated group of patients. Every year, the
patients transit between the health status categories. The
model considers that healed patient will not have hepatitis C
recurrence. The analysis compares the evolution of a disease
treated with PegIFN alpha 2b of 12 kD given subcutaneously,
with a once per week dose of 1.5 mg/kg, associated with oral
ribavirin 1000-1200 mg/day (PegIFN + Rib) or, IFN alpha 2b,
conventional, non-pegylated, given subcutaneously, with
dose of 3 MU three times per week (IFN + Rib), also associated
with oral ribavirin 1,000-1,200 mg/day.
Time Window
Due to the slow progression of chronic hepatitis C [8], the
base case was analyzed for a life-time period.
Clinical Outcomes
The clinical efficacy outcomes used were global SVR, SVR
for genotype 1, and SVR for genotype non-1 [6]. The model
made the extrapolation of these efficacy data for effectiveness
outcomes: number of life years gained and number of quality-
adjusted life years gained.
Delphi Panel
The modified Delphi panels are used in order to obtain
data and develop consensus in pharmacoeconomic studies
[10]. Two rounds of Delphi panels were developed, always
with the same experts, to allow the consensus.
Following categories of professionals were excluded from
the panel: physicians that are somehow linked to the
pharmaceutical industry, such as speakers, consultants, or
employees; or those occupying positions in universities:
professors, lecturers, and physicians occupying positions
within medical associations: directors, presidents. These
professionals were excluded because, as opinion leaders,
during the Delphi panel process they could possibly influence
the opinion of other professionals.
The modified Delphi panel was developed with six
hepatologists; and for the status of hepatocarcinoma and
hepatic encephalopathy, with six oncologists and six
intensivists, respectively.
The local management for the status of mild and moderate
chronic hepatitis C, cirrhosis, ascytis, refractory ascytis,
esophageal varices, hepatic encephalopathy, and hepatic
transplantation were equal for all the studied schemes.
Microcosting and Costs Determination
Microcosting is the process to identify and measure every
resource used, assigning values and integrating such
information thereafter. After this process, all values were
determined for the administration of each therapeutic scheme
as well as their consequences, and costs related to the
evolution of the treated hepatitis C with each treatment
studied.
Discount Rate
The process of “discounting” assumes that the expended
or saved money, and the saved or lost years in the future, do
not have the same value as today. This process decreases the
future costs and life years (consequences), every year,
according to a fixed percentage rate [11].
We used a discount rate of 3% [12]. Sensitivity analyses
were developed with discount rates between 0% and 5%.
Cost-Effectiveness Analysis
The cost-effectiveness analysis compares the costs and
clinical outcomes linked to effectiveness for different
therapeutic alternatives.
The incremental cost-effectiveness rate (ICER) represents
the additional cost and effectiveness obtained, when the
PegIFN + Rib regime is compared to the IFN + Rib regime.
Quality of Life
There are two studies in which the utilities, for every health
states related to chronic hepatitis C, are determined by a panel
of hepatologists familiarized with the disease, and the disease
treatment with interferon [13,14]. In our study, the utility values
for each health states are the same for the PegIFN + Rib arm
and IFN + Rib arm. Table 1 presents the costs and utilities per
every health status used in the model.
Cost-Utility Threshold
There is not an ICU (Incremental Cost-Utility) threshold
in Brazil being considered as ideal for the acceptance of a
given health intervention. Therefore, we used the value
established by the World Health Organization (WHO),
corresponding to three times the per capita gross domestic
Cost Effectiveness Hepatitis C Treatment
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product (GDP), as a threshold for cost-effectiveness/utility
[18,19].
According to the Brazilian Institute of Geography and
Statistics (Instituto Brasileiro de Geografia e Estatística –
IBGE), the 2006 per capita GDP value is R$12,491.00 [20].
Therefore, if a health procedure presents an ICER lower than
R$37,493.00 in Brazil, it may be considered as being cost-
effective.
Sensitivity Analysis and Validation
The role of the sensitivity analysis is to test the stability
of the results when varying different model parameters. These
model parameters are changed, varying their values within a
plausible range found in the literature and checking the related
effect on the global model outcome. If the global outcome of
the strategy under analysis remains stable with the variation
of a given parameter value, then the model outcome is
insensitive to the variation of this parameter being assessed.
The model was recalculated with univariate and bivariate
adjustments.
The sensitivity analysis was performed for the following
parameters inserted in the model:
- Clinical events: transition probability from mild chronic
hepatitis C to remission; from mild chronic hepatitis C to
moderate chronic hepatitis C; from moderate chronic
hepatitis C to cirrhosis; from moderate chronic hepatitis C
to hepatocarcinoma; from cirrhosis to ascytis; from
cirrhosis to hemorrhagic varices; from cirrhosis to hepatic
encephalopathy; from cirrhosis to hepatocarcinoma; from
ascytis to refractory ascytis; from ascytis to death; from
refractory ascytis to death; from hemorrhagic varices to
death in the first year; from hemorrhagic varices to death
in the subsequent years; from hepatic encephalopathy to
death in the first year; from hepatic encephalopathy to
death in the subsequent years; from hepatocarcinoma to
death; from uncompensated cirrhosis to hepatic
transplantation; from hepatic transplantation to death in
the first year; from hepatic transplantation to death in the
subsequent years.
- Economic parameters: cost of mild chronic hepatitis C;
moderate chronic hepatitis C; cirrhosis; ascytis; refractory
ascytis; hemorrhagic varices; hepatic encephalopathy;
hepatocarcinoma; hepatic transplantation; subsequent
years to transplantation; mild hepatitis C utility; moderate
hepatitis C utility; cirrhosis utility; ascytis utility; refractory
ascytis utility; hemorrhagic varices utility; hepatic
encephalopathy utility; hepatocarcinoma utility; hepatic
transplantation utility; hepatic transplantation utility
subsequent years; healed utility; discount rate; price of
the drugs used in the treatment.
As uncertainty could occur with any of the model
parameters, we performed a Monte Carlo simulation with ten
thousand interactions that simultaneously varies all of the
above mentioned parameters. In order to check the internal
validity of our model, we developed many tests and debugging
processes. The external validation was performed comparing
the results projected by the model with external epidemiologic
data not used in this model [21].
Data Sources
The standard treatment and the health care resource
utilization values came from the Delphi panel. The values used
for prices assignment are based on public sources.
Initial Parameters and Probabilities
Initial Parameters
The cohorts that passed through the model simulation
had a 74% prevalence for genotype 1, and 26% for non-1
genotypes [2].
In the simulation, two cohorts received effective
treatment; one of them with conventional IFN alpha 2b,
and the other with PegIFN alpha 2b of 12 kD; the third
cohort simulated the natural disease evolution, without any
treatment.
The average body weight of Brazilian patients receiving
treatment for chronic hepatitis C is 76.7 kg and 64.9 kg for
male and female patients, respectively [22]; therefore, the
ribavirin dose given to these patients is higher than 10.6 mg/
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Table 1. Costs and utilities per health status, per patient.
Health status Cost (R$) [15] Utilities [16]
Remission                                                                                                            789.10 1,00
Mild chronic hepatitis C 1,069.30 0,98
Moderate chronic hepatitis C 1,276.80 0,92
Compensated Cirrhosis 1,522.42 0,82
Ascytis 15,931.79 0,75
Refractory ascytis 31,352.05 0,52
Hemorrhagic varices 21,427.21 0,55
Hepatic encephalopathy 106,922.08 0,53
Hepatocarcinoma 20,884.35 0,55
Hepatic transplantation 136,900.00 0,5 [17]
Subsequent hepatic transplantation 10,540.00 0,7 [17]
Values should be divided by 2.18 in order to convert the economic results to 2006 US dollars.
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kg. Furthermore, we used the response rates being
compatible with the higher dose of ribavirin per kilogram [6].
The treatment time was 48 weeks for genotype 1, and 24
weeks for the other genotypes, for both treatment arms.
Genotype 1 patients were submitted to quantification of
viral titer by means of a PCR test: after 12 weeks in the cohort
with PegIFN alpha 2b, and 24 weeks in the cohort with
conventional IFN [23].
Patients not presenting a significant decrease in their
individual viral load had their treatments interrupted [5, 22].
Probabilities
The probabilities inherent to the natural history of patients
with mild chronic hepatitis C (transition to moderate hepatitis)
and moderate CHC (progression to cirrhosis or
hepatocarcinoma) were obtained from three retrospective
observational studies [24-26]. In patients with mild chronic
hepatitis C, the yearly probability of spontaneous disease
resolution comes from two studies [27,28].
The progression of patients with compensated cirrhosis
(development of hepatocarcinoma and uncompensated
cirrhosis) was based on a study from Fattovich et al. [29]. As
the literature suggests that mortality due to uncompensated
cirrhosis is different, depending on its presentation, we
stratified the uncompensated cirrhosis into different
categories: ascytis, hemorrhagic varices, hepatic
encephalopathy, and ascytis refractory to treatment [8].
In patients with ascytis, after three years of follow-up,
Salerno has detected a yearly mortality of 11% and an
evolution probability to refractory ascytis of 6.7%; for patients
with refractory ascytis, the yearly probability of death
increased to 33% [30].
Patients with hemorrhagic esophageal varices had a
mortality rate of 40%, in the first year, and of 13% in the three
subsequent years of follow-up [31].
For patients presenting hepatic encephalopathy, but
without hemorrhagic varices, the mortality rate was 68% in
the first year, and 40% in the following years [32].
In relation to hepatocarcinoma, the mortality rate is 86% [33].
A total of 792 hepatic transplantations were conducted in
Brazil during 2003 [34]. The overall hepatic transplantation rate
was of 4.95 per million, i.e., 33% of the United States rate, where
the yearly transplantation rate in patients with hepatitis C is
3.1%. In such a way, we estimate the transplantation probability
for hepatitis C patients in Brazil as 1.023% (33% of 3.1%).
The mortality rates for the first post-transplantation year,
and for the subsequent years, come from three studies [35-37].
Table 2 shows the annual probabilities of disease
progression used in this model.
The model assumes for both therapeutic schemes that, in
case of therapeutic failure, the probabilities of disease
progression are the same as the natural disease evolution.
Therefore, the difference between the treatment study arms
are the response rates achieved by the different studied
therapeutic regimes.
Other Causes for Mortality
The yearly risk of death was obtained from the Brazilian
vital statistics [38].
Results
Effectiveness – Life Years Gained
The model projects a life expectation of 18.71 years for the
non-treated patients’ cohort. When adjusted for quality of
life, it is 16.80 years.
There is a gain of 2.23 years (12%) for patients treated
with PegIFN alpha 2b, and of 1.72 (9%) year for those treated
with IFN alpha 2b.
In relation to the IFN alpha 2b regime, the PegIFN regime
resulted in an increase of 2.5% in the global life expectancy, a
life time window.
In patients with genotype 1, PegIFN alpha 2b resulted in
an increase of 2.5% in life expectancy. And the life expectancy
increase was of 1.3% for non-1 genotype patients, with IFN
alpha 2b regime.
Effectiveness – Quality of Life
When the life years gained are adjusted for the quality of
life, the model projects better results for the treated
populations versus the natural disease evolution.
There are gains of 3.39 years for patients treated with
PegIFN alpha 2b (20%), and 2.61 years for patients treated
with IFN alpha 2b (15.5%).
The PegIFN alpha 2b regimen resulted in an increase of
4% in quality adjusted life years gained, corresponding to
0.78 quality adjusted life years gained in relation to the IFN
alpha 2b regimen.
In the non-1 genotype patients, the treatment with PegIFN
alpha 2b resulted in an increase of 2% in the patients’ quality
adjusted life expectancy, meaning 0.44 quality adjusted life
years in an entire life window, in relation to the IFN alpha 2b
regime.
Economical Results
The average cost of a patient with chronic hepatitis C
along an entire life is R$39,147.32.
Considering the life time window, the average cost
discounted by 3%, for the patient who received PegIFN alpha
2b was of R$59,782.93; and for the patient who received IFN
alpha 2b was of R$44,334.25.
The costs for the health states of mild chronic hepatitis C
and moderate chronic hepatitis C are equal for the three studied
cohorts (patients without treatment, being treated with PegIFN
alpha 2b or, otherwise, conventional IFN alpha 2b), because
none of these patients received treatment yet, and all of them
will be treated at the same time, in all cohorts.
The costs related to all health states are constantly higher
for non-treated patients, except for mild chronic hepatitis C
and moderate chronic hepatitis C.
The patients treated with PegIFN alpha 2b present lower
cost in all health states following moderate chronic hepatitis
Cost Effectiveness Hepatitis C Treatment
www.bjid.com.br
BJID 2009; 13 (June) 195Cost Effectiveness Hepatitis C Treatment
C, irrespective to the viral genotype. The area under the
expenses curve in relation to time of the health states of
cirrhosis, uncompensated cirrhosis, hepatic transplantation,
and hepatic transplantation-subsequent years for IFN alpha
2b is higher than for PegIFN alpha 2b, not only due to the
higher costs achieved, but also because these costs remain in
such high levels longer than for PegIFN alpha 2b.
Cost-Utility
In an entire life time window, within the global population,
there is a gain of 0.78 quality adjusted with PegIFN alpha 2b
compared to IFN alpha 2b, however, there is also an
incremental cost of R$15,448.68. Therefore, the point estimate
cost-utility of PegIFN alpha 2b in relation to IFN alpha 2b is
R$19,848.34. The cost utility rates of PegIFN alpha 2b and IFN
alpha 2b in relation to no treatment are R$6,087.20 and
R$1,987.33, respectively.
Sensitivity Analysis – Marginal Cost-Utility
In the univariate analysis, the incremental cost-utility varied
between R$14,322.93 and R$32,436.38 for each quality adjusted
life year gained, after the variation of transition probabilities
and costs within the range of plausible values, and increasing
or decreasing by 50% the costs of the different health states.
The model was insensitive to all univariate variations of
transition probabilities and costs.
In a bivariate analysis, using the clinical and economical
parameters with the widest variation, transition probability of
mild chronic hepatitis C to remission and discount rate,
respectively for the whole population, the incremental cost-
utility is sensitive to a discount level of 5%, unless the
spontaneous remission is probability higher than 0.001 yearly.
This same analysis splitting the population in patients with
genotype 1 and non-1 has demonstrated that for genotype 1
patients, the incremental cost-utility is sensitive to a discount
level of 5%, unless the spontaneous remission probability is
higher than 0.004 yearly. For patients with non-1 genotype
virus, the incremental cost-utility was never above R$37,493.00,
even when the discount rate was 5%, and the spontaneous
remission probability lower than 0.000 yearly.
Monte Carlo Probabilistic Sensitivity Analysis
Within an entire life time window, the mean cost-utility
obtained through the Monte Carlo simulation with ten
thousand interactions for the whole cohort, for patients with
chronic hepatitis C due to genotype 1 virus, and due to
genotype non-1 virus was of R$17,774.10, R$16,523.62, and
R$12,583.45, respectively.
The outcomes of the Monte Carlo simulation are shown in
Figures 1 and 2, in which the cost-utility rate is presented as a
function of a threshold rate. This “threshold -rate” is that
which a given healthcare decision maker or payer would be
willing to pay, to include a given drug into his/her formulary.
For genotype 1 CHC patients, the cost-utility rate found in
the model (R$23,392.18) presents an acceptance probability
around 68%, while 90% of the 10,000 results obtained in the
Monte Carlo simulation are below the limit of R$37,493.00
considered, in Brazil, and according to the WHO criteria, as
the “threshold -rate” of cost-effectiveness/utility.
For patients with genotype non-1, the cost-utility rate
found in the model (R$17,083.54) presents a probability to be
accepted around 65%. We also verified that 95% of the 10,000
results obtained in the Monte Carlo simulation are below the
limit of R$37,493.00.
Table 2. Yearly probabilities of disease progression in patients with chronic hepatitis C [13].
Initial status Event (Reference) Yearly probability (%)
Mild chronic hepatitis Remission 0.2
Moderate chronic hepatitis C 4.1






Ascytis Refractory ascytis 6.7
Death 11.0
Refractory ascytis Death 33.0
Hemorrhagic varices Death 1st year 40.0
Death subsequent years 13.0
Hepatic encephalopathy Death 1st year 68.0
Death subsequent years 40.0
Hepatocarcinoma Death 86.0
Uncompensated Cirrhosis Hepatic transplantation 1.023
Hepatic transplantation Death 1st year 21.0
Death subsequent years 5.7
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Model Validation
The external model validation was performed comparing
the cirrhosis development probability, after 20 years of
evolution of chronic hepatitis C, projected by the model, with
the same parameter extracted from studies examining the long-
term prognosis of chronic hepatitis C. The probability of
developing cirrhosis, after 20 years of natural disease evolution
estimated by our model, was of 17.3%, which is consistent with
the same probability published in other studies [21,39 - 43].
Discussion
This study examined the effectiveness and cost-
effectiveness (utility) of treating chronic hepatitis C with
PegIFN alpha 2b of 12 kD, compared to IFN alpha 2b
(conventional) regimen in Brazilian patients, 30 years of age
in average, using a Markov model to estimate the incremental
cost-utility (ICU) in such patients, in the Brazilian 2006 private
healthcare setting perspective.
The outcomes projected by this model were compared to
the epidemiological data not used to build the model [21]. The
epidemiological data usually used for this purpose was the
probability to develop cirrhosis after 20 years of chronic
hepatitis C natural evolution [21,39,42]. A 17.3% probability
was estimated in a cohort of patients with mild chronic hepatitis
C, a value being consistent and coherent with the published
studies [21,39-43]. Therefore, the model probably represents
with good accuracy the expected course of this disease, in
the absence of antiviral treatment [21].
Additionally, the model projected the life expectation and
quality adjusted life years for patients receiving no treatment,
and achieved results being quite consistent with those from
other already published models [21].
The therapeutic regime with PegIFN alpha 2b produced
an average survival benefit of 0.51 discounted year of life,
compared to IFN alpha 2b, in a life-time window. Although a
gain of six incremental months of survival could appear tiny, it
is consistent with the benefit resulting from other interventions
to treat hepatitis C [21].
In genotype 1 patients, the cost-utility rate of PegIFN alpha
2b compared to IFN alpha 2b is higher because these patients
should be treated for a longer time (48 weeks), have a SVR rate
being lower than those for genotype 2 and 3 patients and,
hence, they have a higher number of complications resulting
from the disease evolution and, consequently, higher expenses
and healthcare resources consumption.
The opposite occurs in genotype 2 and 3 patients. They
are treated for a shorter period of time, 24 weeks, have higher
SVR rate, with lower number of complications due to disease
evolution and, therefore, lower consumption of healthcare
resources.
However, genotype 1 patients generate larger benefit, in
terms of life expectation and quality, in a life-time window,
compared to IFN alpha 2b patients.
We could observe as well, that cirrhosis and its
complications are the health statuses generating the main
differences, in terms of financial resources consumption,
between the regimes with PegIFN alpha 2B and conventional
IFN alpha 2b.
The expenditure with drugs is 87.6% larger with the PegIFN
alpha 2b therapy, but the cost incurred with the disease
evolution treatment is 30% higher with the IFN alpha 2b
therapy. Overall, the costs of PegIFN alpha 2b are 34.8% higher
than those with IFN alpha 2b. However, with the cost-utility
calculations, we could observe that, despite of being more
expensive, the PegIFN alpha 2b treatment is cost-effective,
seen under the WHO point of view related to the Brazilian
healthcare market [15,16]. This result does not modify when
we separately analyze both patients populations, genotype 1
and non-1 patients.
The global calculated cost-utility, R$19,848.34 per quality-
adjusted life year gained is a single point estimation, is
subjected to biases due to the uncertainties inherent to the
model parameters. These uncertainties were considered by
the sensitivity analyses and Monte Carlo simulations.
The incremental cost-utility rates are stable in the vast
majority of circumstances, as duly shown by the Monte Carlo
simulations.
The Monte Carlo simulation shows that the treatment with
PegIFN alpha 2b, along an entire life time window, is cost-
effective in 90.27% and 95.54% of the times, for patients with
HCV genotypes 1 and non-1, respectively. This means that, if
we consider the value of R$37,493.00, which according to the
WHO suggestion is the threshold cost-utility ratio, PegIFN
alpha 2b would have a probability of 90.27% for patients with
genotype 1 HCV, and of 95.54% for patients with genotype
non-1 HCV, to be accepted as a cost-effective treatment of
chronic hepatitis C.
Except for a single work [21], “utilities” based on patients
or on the community are not available, therefore, the patients’
preferences have been estimated by experts [8,13,44]. Given
the limited data coming directly from patients, we decided to
use the already recognized data from literature [8,13].
We should emphasize that the “utilities” used in this model,
despite being classic, are lower than those presented in other
works [21].
Another topic to be commented is the possibility of our
study underestimate the costs related to disease and,
probably, underestimate the resource savings resulting from
the treatment itself, due to the avoidance of future clinical
complications. We used variable costs and have not considered
fixed costs, not even those related to loss of productivity.
The model also does not include the cost of other treatments
for non-responsive patients and, the histological
normalization and decrease of hepatocarcinoma incidence in
non-responsive patients were not considered, as well.
Limitations of this Model
The clinical impact of the PegIFN alpha 2b regime was
based only in a single clinical trial, by Manns et al., published
at Lancet in 2001 [6].
Cost Effectiveness Hepatitis C Treatment
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Figure 1. Probability of PegIFN alpha 2b being cost effective as a function of a cost utility threshold for patients with genotype
1 chronic hepatitis C
Figure 2. Probability of PegIFN alpha 2b being cost effective as a function of a cost utility threshold for patients with genotype
2 chronic hepatitis C
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Because we do not have “utilities” described for the
different chronic hepatitis C health states for Brazilian
patients, the quality adjusted life years may be subject of
criticism.
The average clinical management was obtained from
Delphi panels with Brazilian hepatologists, oncologists and
intensivists; nevertheless, some variability in the cases
management is possible, causing some cost differences. Then
again, the sensitivity analysis studied this, and the model
was not sensitive to these cost parameters.
Although there are many other possible health states that
could be inserted in a chronic hepatitis C model, the
simplification of the states and their transitions was necessary,
in order to obtain a usable Markov model.
But, besides these limitations in the modeling technique,
there are advantages that should be pointed out.
The ideal design to demonstrate the possible PegIFN alpha
2b regime long-term economic outcomes benefit compared to
IFN alpha 2b regime, would be a naturalistic prospective study,
which would require a long follow-up period under the
economic perspective (from 15 to 35 years); and this is not
feasible.
The use of decision techniques allows the extrapolation
of clinical outcomes, beyond the duration of available clinical
trials. Validation and sensitivity analyses were performed when
feeling that the uncertainty would be big. In this model, the
sensitivity analyses have been done with health states costs,
utilities, and transition probabilities. These analyses
demonstrate the results robustness in relation to the base-
case parameters variation.
Conclusion
The results from this model suggest that the regimen with
PegIFN alpha 2b is cost-effective compared to the IFN alpha
2b regimen, in patients with chronic hepatitis C. PegIFN alpha
2b is important in the global treatment cost of patients with
chronic hepatitis C, however, this apparently voluminous initial
investment decreases substantially the subsequent costs due
to the chronic disease progression.
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